OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.050
-0.024 (-0.78%)
Apr 24, 2026, 3:14 PM CET
OSE Immunotherapeutics Employees
OSE Immunotherapeutics had 64 employees as of December 31, 2024. The number of employees increased by 9 or 16.36% compared to the previous year.
Employees
64
Change (1Y)
9
Growth (1Y)
16.36%
Revenue / Employee
€27,844
Profits / Employee
€508,109
Market Cap
68.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 64 | 9 | 16.36% |
| Dec 31, 2023 | 55 | -12 | -17.91% |
| Dec 31, 2022 | 67 | 6 | 9.84% |
| Dec 31, 2021 | 61 | 10 | 19.61% |
| Dec 31, 2020 | 51 | 9 | 21.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 174 |
| genOway Société anonyme | 148 |
| Transgene | 145 |
| Adocia | 77 |
| MaaT Pharma | 65 |
| Fermentalg | 63 |
| Sensorion | 63 |
| ABIONYX Pharma | 51 |
OSE Immunotherapeutics News
- 1 day ago - OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting - GlobeNewsWire
- 9 days ago - OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting - GlobeNewsWire
- 9 days ago - OSE Immunotherapeutics Evolves its Leadership Team - GlobeNewsWire
- 4 weeks ago - OSE Immunotherapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - OSE Immunotherapeutics Announces its 2026 Financial Calendar - GlobeNewsWire
- 6 weeks ago - OSE Immunotherapeutics Confirms Marc Le Bozec As CEO To Drive Next Phase Of Growth - Nasdaq
- 7 weeks ago - OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® - GlobeNewsWire
- 3 months ago - OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab - GlobeNewsWire